AustralianSuper Pty Ltd Takes Position in Glaukos Corporation $GKOS

AustralianSuper Pty Ltd purchased a new stake in shares of Glaukos Corporation (NYSE:GKOS) in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm purchased 406,096 shares of the medical instruments supplier’s stock, valued at approximately $41,946,000. AustralianSuper Pty Ltd owned about 0.71% of Glaukos as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also recently modified their holdings of the business. Teacher Retirement System of Texas raised its stake in shares of Glaukos by 3.3% during the second quarter. Teacher Retirement System of Texas now owns 19,948 shares of the medical instruments supplier’s stock valued at $2,060,000 after acquiring an additional 628 shares during the last quarter. Bessemer Group Inc. raised its stake in Glaukos by 2,270.3% during the second quarter. Bessemer Group Inc. now owns 6,542 shares of the medical instruments supplier’s stock worth $675,000 after buying an additional 6,266 shares during the last quarter. Envestnet Asset Management Inc. raised its stake in Glaukos by 72.8% during the second quarter. Envestnet Asset Management Inc. now owns 48,439 shares of the medical instruments supplier’s stock worth $5,003,000 after buying an additional 20,401 shares during the last quarter. Oppenheimer Asset Management Inc. raised its stake in Glaukos by 245.6% during the second quarter. Oppenheimer Asset Management Inc. now owns 14,297 shares of the medical instruments supplier’s stock worth $1,477,000 after buying an additional 10,160 shares during the last quarter. Finally, State of New Jersey Common Pension Fund D raised its stake in Glaukos by 4.2% during the second quarter. State of New Jersey Common Pension Fund D now owns 19,905 shares of the medical instruments supplier’s stock worth $2,056,000 after buying an additional 800 shares during the last quarter. Institutional investors own 99.04% of the company’s stock.

Glaukos Trading Down 0.9%

GKOS opened at $74.60 on Monday. Glaukos Corporation has a 1-year low of $73.73 and a 1-year high of $163.71. The company has a current ratio of 5.51, a quick ratio of 4.69 and a debt-to-equity ratio of 0.09. The company has a market cap of $4.28 billion, a P/E ratio of -45.21 and a beta of 0.76. The company has a fifty day moving average price of $86.40 and a two-hundred day moving average price of $91.89.

Glaukos (NYSE:GKOS) last posted its quarterly earnings results on Wednesday, July 30th. The medical instruments supplier reported ($0.24) earnings per share for the quarter, beating the consensus estimate of ($0.26) by $0.02. The firm had revenue of $124.12 million during the quarter, compared to the consensus estimate of $115.49 million. Glaukos had a negative net margin of 21.43% and a negative return on equity of 8.59%. The business’s revenue was up 29.7% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.52) earnings per share. Glaukos has set its FY 2025 guidance at EPS. Analysts predict that Glaukos Corporation will post -1.08 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on the stock. Wells Fargo & Company lifted their target price on shares of Glaukos from $86.00 to $92.00 and gave the stock an “equal weight” rating in a research note on Thursday, July 31st. Zacks Research downgraded shares of Glaukos from a “strong-buy” rating to a “hold” rating in a research note on Friday, August 15th. Mizuho set a $130.00 target price on shares of Glaukos in a research note on Thursday, July 31st. BTIG Research reaffirmed a “buy” rating and issued a $104.00 price target on shares of Glaukos in a research note on Monday, October 20th. Finally, Truist Financial decreased their price target on shares of Glaukos from $126.00 to $120.00 and set a “buy” rating for the company in a research note on Monday, September 22nd. One analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, two have given a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $116.92.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.